A 802715

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 571203

CAS#: 107767-58-8

Description: A 802715 is an anti-tumor agent that causes dose-dependent protection against lipopolysaccharide induced lethal shock. It counteracts tumor necrosis factor alpha toxicity. It may regulate cell growth and damage response in human cancer tumor cells.


Chemical Structure

img
A 802715
CAS# 107767-58-8

Theoretical Analysis

MedKoo Cat#: 571203
Name: A 802715
CAS#: 107767-58-8
Chemical Formula: C16H26N4O3
Exact Mass: 322.20
Molecular Weight: 322.410
Elemental Analysis: C, 59.61; H, 8.13; N, 17.38; O, 14.89

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: A 802715; A-802715; A802715

IUPAC/Chemical Name: 1H-Purine-2,6-dione, 3,7-dihydro-1-(5-hydroxy-5-methylhexyl)-3-methyl-7-propyl-

InChi Key: SBKAARSDXHSHSM-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H26N4O3/c1-5-9-19-11-17-13-12(19)14(21)20(15(22)18(13)4)10-7-6-8-16(2,3)23/h11,23H,5-10H2,1-4H3

SMILES Code: O=C(N1CCCCC(C)(O)C)N(C)C2=C(N(CCC)C=N2)C1=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 322.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Bohm L, Theron T, Binder A. Influence of pentoxifylline, A-802710, propentofylline and A-802715 (Hoechst) on the expression of cell cycle blocks and S-phase content after irradiation damage. Biochim Biophys Acta. 2000 Dec 11;1499(1-2):1-10. PubMed PMID: 11118634.

2: Niehörster M, Schönharting M, Wendel A. A novel xanthine derivative counteracting in vivo tumor necrosis factor alpha toxicity in mice. Circ Shock. 1992 Aug;37(4):270-3. PubMed PMID: 1446384.

3: Hoffmann H, Weis M, Frank G, Birg A, Schönharting MM, Jochum M. Amelioration of endotoxin-induced acute lung injury in pigs by HWA 138 and A 80 2715: new analogs of pentoxifylline. Shock. 1995 Sep;4(3):166-70. PubMed PMID: 8574750.

4: Leist M, Auer-Barth S, Wendel A. Tumor necrosis factor production in the perfused mouse liver and its pharmacological modulation by methylxanthines. J Pharmacol Exp Ther. 1996 Mar;276(3):968-76. PubMed PMID: 8786577.

5: Entzian P, Bitter-Suermann S, Burdon D, Ernst M, Schlaak M, Zabel P. Differences in the anti-inflammatory effects of theophylline and pentoxifylline: important for the development of asthma therapy? Allergy. 1998 Aug;53(8):749-54. PubMed PMID: 9722223.

6: Semmler J, Gebert U, Eisenhut T, Moeller J, Schönharting MM, Alléra A, Endres S. Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity. Immunology. 1993 Apr;78(4):520-5. PubMed PMID: 8388363; PubMed Central PMCID: PMC1421886.

7: Lin Y, Goebels J, Rutgeerts O, Kasran A, Van Gool S, Ceuppens J, Schönharting M, Waer M. Use of the methylxanthine derivative A802715 in transplantation immunology: I. Strong in vitro inhibitory effects on CD28-costimulated T cell activities. Transplantation. 1997 Jun 27;63(12):1813-8. PubMed PMID: 9210510.

8: Rieneck K, Diamant M, Haahr PM, Schönharting M, Bendtzen K. In vitro immunomodulatory effects of pentoxifylline. Immunol Lett. 1993 Aug;37(2-3):131-8. PubMed PMID: 7505000.

9: Lin Y, Segers C, Mikhalsky D, Schönharting M, Waer M. Xanthines: ideal immunosuppressants for combination with cyclosporine? Transplant Proc. 1996 Dec;28(6):3102. PubMed PMID: 8962202.

10: Lin Y, Segers C, Mikhalsky D, Tjandra-Maga TB, Schönharting M, Waer M. Use of the methylxanthine derivative A802715 in transplantation immunology: II. In vivo experiments. Transplantation. 1997 Jun 27;63(12):1734-8. PubMed PMID: 9210496.

11: Lin Y, Schönharting M, Goebels J, Rutgeerts O, Mikhalsky D, Waer M. Use of methylxanthines (MeXa) as immunosuppressive drugs for organ transplantation. Transplant Proc. 1997 Feb-Mar;29(1-2):1279. PubMed PMID: 9123305.